1.Identification
1.1 GHS Product identifier
| Product name | L-(-)-α-Methyldopa |
|---|
1.2 Other means of identification
| Product number | - |
|---|---|
| Other names | Methyldopa Sesquihydrate |
1.3 Recommended use of the chemical and restrictions on use
| Identified uses | For industry use only. |
|---|---|
| Uses advised against | no data available |
1.4 Supplier's details
| Company | MOLBASE (Shanghai) Biotechnology Co., Ltd. |
|---|---|
| Address | Floor 4 & 5, Building 12, No. 1001 North Qinzhou Road, Xuhui District, Shanghai, China |
| Telephone | +86(21)64956998 |
| Fax | +86(21)54365166 |
1.5 Emergency phone number
| Emergency phone number | +86-400-6021-666 |
|---|---|
| Service hours | Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours). |
2.Hazard identification
2.1 Classification of the substance or mixture
Reproductive toxicity, Category 2
2.2 GHS label elements, including precautionary statements
| Pictogram(s) |  |
|---|---|
| Signal word | Warning |
| Hazard statement(s) | H361 Suspected of damaging fertility or the unborn child |
| Precautionary statement(s) | |
| Prevention | P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/protective clothing/eye protection/face protection. |
| Response | P308+P313 IF exposed or concerned: Get medical advice/ attention. |
| Storage | P405 Store locked up. |
| Disposal | P501 Dispose of contents/container to ... |
2.3 Other hazards which do not result in classification
none
3.Composition/information on ingredients
3.1 Substances
| Chemical name | Common names and synonyms | CAS number | EC number | Concentration |
|---|---|---|---|---|
| L-(-)-α-Methyldopa | L-(-)-α-Methyldopa | 555-30-6 | none | 100% |
4.First-aid measures
4.1 Description of necessary first-aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
4.2 Most important symptoms/effects, acute and delayed
SYMPTOMS: Symptoms of exposure to this compound include edema (fluid retention), fever, diarrhea, mental depression, hepatic toxicity, arthralgia (with or without joint swelling), leukopenia, breast enlargement, amenorrhea, pancreatitis, myocarditis and hemolytic anemia. Parkinsonism, hypertension and galactorrhea (lactation) may occur. Reversible keratitis may also occur. Other symptoms include sedation (usually transient), asthenia, congestive heart failure, weight gain, vomiting, sialadenitis, sore or "black" tongue, distention, flatus, hyperprolactinemia, bone marrow depression, rheumatoid factor, abnormal liver function tests, pericarditis, decreased mental acuity, symptoms of cerebrovascular insufficiency, psychic disturbances including nightmares and reversible mild psychoses, rise in BUN, toxic epidermal necrosis and decreased libido. Exposure can cause headache, weakness, aggravation of angina pectoris, prolonged carotid sinus hypersensitivity, postural hypotension, bradycardia, colitis, nausea, constipation, dryness of the mouth, granulocytopenia, thrombocytopenia, positive tests for antinuclear antibody, LE cells, positive Coombs test, liver disorders including hepatitis and jaundice, lupus-like syndrome, Bell's palsy, involuntary choreoathetotic movements, dizziness, lightheadedness, paresthesias, myalgia, nasal stuffiness, skin rash and impotence. Exposure can also cause drowsiness, gastrointestinal upset, disorders of sexual function, salivary gland inflammation, uremia, liver damage (including cirrhosis), darkened urine, eosinophilia, syncope, cholestasis, eczema, oral ulceration, hyperpyrexia, ocular disturbances, febrile reaction, joint pain, nodular skin lesions, retroperitoneal fibrosis and biliary carcinoma. There has been a case of reversible malabsorption with partial villous atrophy, inflammatory infiltrate of the mucosa and giant-cell granuloma. Other symptoms may include sleep disturbances, anxiety, blurred vision, hepatic necrosis and lichenoid and granulomatous skin reactions. It may also cause menstrual cycle changes or disorders and effects on the newborn including abnormal neonatal measures, growth statistics and biochemical and metabolic changes. ACUTE/CHRONIC HAZARDS: When heated to decomposition this compound emits toxic fumes of nitrogen oxides.
4.3 Indication of immediate medical attention and special treatment needed, if necessary
... AFTER DISCONTINUATION OF METHYLDOPA... HEMOLYTIC ANEMIA USUALLY RESOLVES WITHIN A MATTER OF WEEKS. SEVERE HEMOLYSIS MAY BE ATTENUATED BY TREATMENT WITH GLUCOCORTICOIDS.
5.Fire-fighting measures
5.1 Extinguishing media
Suitable extinguishing media
Fires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher.
5.2 Specific hazards arising from the chemical
Flash point data for this chemical are not available; however, it is probably combustible.
5.3 Special protective actions for fire-fighters
Wear self-contained breathing apparatus for firefighting if necessary.
6.Accidental release measures
6.1 Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. For personal protection see section 8.
6.2 Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment must be avoided.
6.3 Methods and materials for containment and cleaning up
Pick up and arrange disposal. Sweep up and shovel. Keep in suitable, closed containers for disposal.
7.Handling and storage
7.1 Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Avoid exposure - obtain special instructions before use.Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2.
7.2 Conditions for safe storage, including any incompatibilities
Methyldopa oral suspension should be stored in tight, light-resistant containers at a temperature less than 26°C and protected from freezing. Methyldopa tablets should be stored in well-closed containers at a temperature less than 40°C, preferably at 15-30°C.
8.Exposure controls/personal protection
8.1 Control parameters
Occupational Exposure limit values
no data available
Biological limit values
no data available
8.2 Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.
8.3 Individual protection measures, such as personal protective equipment (PPE)
Eye/face protection
Safety glasses with side-shields conforming to EN166. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Wear impervious clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique(without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.
Respiratory protection
Wear dust mask when handling large quantities.
Thermal hazards
no data available
9.Physical and chemical properties
| Physical state | Colorless or almost colorless crystals or white to yellowish-white fine powder. Almost tasteless. In the sesquihydrate form. |
|---|---|
| Colour | Minute, anhyd crystals from methanol |
| Odour | ODORLESS |
| Melting point/ freezing point | 182°C(lit.) |
| Boiling point or initial boiling point and boiling range | 70°C/32mmHg(lit.) |
| Flammability | no data available |
| Lower and upper explosion limit / flammability limit | no data available |
| Flash point | 52°C(lit.) |
| Auto-ignition temperature | no data available |
| Decomposition temperature | no data available |
| pH | pH of saturated aq soln about 5.0 |
| Kinematic viscosity | no data available |
| Solubility | In water:SolubleSolubility:Soluble in DMSO (75 mM), water, and dilute hydrochloric acid. |
| Partition coefficient n-octanol/water (log value) | no data available |
| Vapour pressure | no data available |
| Density and/or relative density | 1.403g/cm3 |
| Relative vapour density | no data available |
| Particle characteristics | no data available |
10.Stability and reactivity
10.1 Reactivity
no data available
10.2 Chemical stability
RELATIVELY STABLE IN BOTH LIGHT & AIR
10.3 Possibility of hazardous reactions
METHYL DOPA undergoes catalytic oxygenation in the presence of magnesium, cupric, cobalt, nickel and ferric ions . A weakly acidic amino acid.
10.4 Conditions to avoid
no data available
10.5 Incompatible materials
no data available
10.6 Hazardous decomposition products
When heated to decomposition it emits toxic fumes of nitroxides.
11.Toxicological information
Acute toxicity
- Oral: LD50 Rat oral 5000 mg/kg
- Inhalation: no data available
- Dermal: no data available
Skin corrosion/irritation
no data available
Serious eye damage/irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
no data available
Reproductive toxicity
no data available
STOT-single exposure
no data available
STOT-repeated exposure
no data available
Aspiration hazard
no data available
12.Ecological information
12.1 Toxicity
- Toxicity to fish: no data available
- Toxicity to daphnia and other aquatic invertebrates: no data available
- Toxicity to algae: no data available
- Toxicity to microorganisms: no data available
12.2 Persistence and degradability
no data available
12.3 Bioaccumulative potential
no data available
12.4 Mobility in soil
no data available
12.5 Other adverse effects
no data available
13.Disposal considerations
13.1 Disposal methods
Product
The material can be disposed of by removal to a licensed chemical destruction plant or by controlled incineration with flue gas scrubbing. Do not contaminate water, foodstuffs, feed or seed by storage or disposal. Do not discharge to sewer systems.
Contaminated packaging
Containers can be triply rinsed (or equivalent) and offered for recycling or reconditioning. Alternatively, the packaging can be punctured to make it unusable for other purposes and then be disposed of in a sanitary landfill. Controlled incineration with flue gas scrubbing is possible for combustible packaging materials.
14.Transport information
14.1 UN Number
| ADR/RID: UN1993 | IMDG: UN1993 | IATA: UN1993 |
14.2 UN Proper Shipping Name
| ADR/RID: FLAMMABLE LIQUID, N.O.S. |
| IMDG: FLAMMABLE LIQUID, N.O.S. |
| IATA: FLAMMABLE LIQUID, N.O.S. |
14.3 Transport hazard class(es)
| ADR/RID: 3 | IMDG: 3 | IATA: 3 |
14.4 Packing group, if applicable
| ADR/RID: III | IMDG: III | IATA: III |
14.5 Environmental hazards
| ADR/RID: no | IMDG: no | IATA: no |
14.6 Special precautions for user
no data available
14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
no data available
15.Regulatory information
15.1 Safety, health and environmental regulations specific for the product in question
| Chemical name | Common names and synonyms | CAS number | EC number |
|---|---|---|---|
| L-(-)-α-Methyldopa | L-(-)-α-Methyldopa | 555-30-6 | none |
| European Inventory of Existing Commercial Chemical Substances (EINECS) | Listed. | ||
| EC Inventory | Listed. | ||
| United States Toxic Substances Control Act (TSCA) Inventory | Listed. | ||
| China Catalog of Hazardous chemicals 2015 | Not Listed. | ||
| New Zealand Inventory of Chemicals (NZIoC) | Listed. | ||
| Philippines Inventory of Chemicals and Chemical Substances (PICCS) | Not Listed. | ||
| Vietnam National Chemical Inventory | Listed. | ||
| Chinese Chemical Inventory of Existing Chemical Substances (China IECSC) | Not Listed. | ||
16.Other information
Information on revision
| Creation Date | Aug 12, 2017 |
|---|---|
| Revision Date | Aug 12, 2017 |
Abbreviations and acronyms
- CAS: Chemical Abstracts Service
- ADR: European Agreement concerning the International Carriage of Dangerous Goods by Road
- RID: Regulation concerning the International Carriage of Dangerous Goods by Rail
- IMDG: International Maritime Dangerous Goods
- IATA: International Air Transportation Association
- TWA: Time Weighted Average
- STEL: Short term exposure limit
- LC50: Lethal Concentration 50%
- LD50: Lethal Dose 50%
- EC50: Effective Concentration 50%
References
- IPCS - The International Chemical Safety Cards (ICSC), website: http://www.ilo.org/dyn/icsc/showcard.home
- HSDB - Hazardous Substances Data Bank, website: https://toxnet.nlm.nih.gov/newtoxnet/hsdb.htm
- IARC - International Agency for Research on Cancer, website: http://www.iarc.fr/
- eChemPortal - The Global Portal to Information on Chemical Substances by OECD, website: http://www.echemportal.org/echemportal/index?pageID=0&request_locale=en
- CAMEO Chemicals, website: http://cameochemicals.noaa.gov/search/simple
- ChemIDplus, website: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp
- ERG - Emergency Response Guidebook by U.S. Department of Transportation, website: http://www.phmsa.dot.gov/hazmat/library/erg
- Germany GESTIS-database on hazard substance, website: http://www.dguv.de/ifa/gestis/gestis-stoffdatenbank/index-2.jsp
- ECHA - European Chemicals Agency, website: https://echa.europa.eu/
